Today: 8 February 2026
Subscribe
Browse Category

Pharmaceuticals News 14 December 2025 - 16 December 2025

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics shares fell about 6% to $60.73 Tuesday, swinging between $58.95 and $65.69 intraday after recent gains. The drop followed positive Phase 2b results for its oral obesity drug aleniglipron and a $747.5 million equity raise. Trading volume was below average, with some reports noting declines up to 9% during the session.
16 December 2025
···
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals shares fell about 9% Tuesday, trading near $62 after touching an intraday low of $59.76. The decline follows a recent surge to a 52-week high after FDA approval of its first drug, REDEMPLO, and an FDA Breakthrough Therapy designation. No single negative catalyst was cited; analysts pointed to profit-taking and volatility after recent gains. Arrowhead also disclosed routine equity grants for new hires.
16 December 2025
··
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer shares fell nearly 5% to about $25 in U.S. trading Tuesday after the company issued 2026 guidance with adjusted EPS of $2.80–$3.00, below Wall Street estimates. The stock reversed early gains as investors reacted to lower COVID-19 sales and patent expirations expected to pressure results next year. Trading volume topped 55 million shares by late morning.
16 December 2025
····
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson shares fell about 1% to $211–$212 late Tuesday morning after hitting recent highs, following news that the FDA granted a National Priority Voucher for its Tecvayli and Darzalex combination therapy for multiple myeloma. The FDA highlighted strong Phase 3 results and rapid review plans. Investors await the company’s upcoming earnings update for further guidance.
16 December 2025
···
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, both below Wall Street estimates. The company cited falling COVID-19 product sales and loss of exclusivity for key drugs as main drags. Shares were little changed Tuesday after the update. Pfizer expects about $5 billion in COVID product revenue for 2026, down from $6.5 billion in 2025.
16 December 2025
···
Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. (NYSE: PFE) heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas (immunology and obesity), and a regulatory backdrop that can flip sentiment faster than a lab centrifuge. Shares closed Monday at $26.43, up 2.24%, extending a four-session winning streak, according to MarketWatch. MarketWatch On the data side, Pfizer’s own calendar is the center of gravity: the company is scheduled to host an 8:00 a.m. EST analyst call today to provide full-year 2026 financial guidance. Pfizer+1 Below is what’s driving
16 December 2025
···
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics shares rose 8%–11% in pre-market trading December 16 ahead of topline results from its Phase 2b REZOLVE-AA trial in severe-to-very-severe alopecia areata. The company will release data and hold an investor call at 8:00 a.m. ET. The trial enrolled about 90 patients and tested rezpegaldesleukin against placebo, with the primary endpoint at 36 weeks.
16 December 2025
··
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK shares closed at 1,833.50p in London on Dec. 15, up 0.49%, with the US ADR trading near $49.24. The UK approved Exdensur (depemokimab), the first twice-yearly asthma biologic, for asthma and chronic rhinosinusitis with nasal polyps. European and US regulators also advanced GSK’s respiratory and vaccine programs. GSK’s stock is up nearly 38% over the past year.
16 December 2025
··
Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck shares traded near $99.59 Monday afternoon, down 0.23%, after Bank of America raised its price target to $120 and reiterated a Buy rating. The move followed a positive European CHMP opinion on Winrevair and a higher dividend as the stock hit its ex-dividend date. Investors weighed these developments against ongoing regulatory scrutiny and questions about Merck’s post-Keytruda strategy.
15 December 2025
··
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals confirmed CEO Rich Daly will present at the J.P. Morgan Healthcare Conference on January 12, 2026. CPRX traded near $23.95 Monday, below the $26.58 technical level watched by traders. Shares saw volume around 822,000 and a Relative Strength Rating increase from 61 to 73. Analysts cited ongoing debate over the stock’s next move after a strong year.
15 December 2025
·
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly shares rose about 2% to $1,048.47 in early trading Monday after new Phase 3 data showed retatrutide led to nearly 29% weight loss in patients with obesity and knee osteoarthritis. Bank of America trimmed its price target on LLY to $1,268 but kept a “buy” rating. Investors are also watching FDA review timing for orforglipron and ongoing U.S. capacity expansion.
15 December 2025
··
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi shares fell about 4% in Paris on December 15 after the company reported a U.S. regulatory delay for tolebrutinib in non-relapsing secondary progressive MS and a failed Phase 3 trial in primary progressive MS. Sanofi will not seek approval for the latter indication. The FDA decision for nrSPMS is now expected after December 28, with further guidance by end of Q1 2026.
15 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals shares closed Friday at $452.04, up 1.37%, extending a three-day rally but still 13% below the March high of $519.68. Trading volume topped 1.6 million shares, above the 50-day average. A Morgan Stanley upgrade and optimism over Vertex’s kidney disease pipeline have driven recent swings. New pediatric data for gene-editing therapy Casgevy drew attention at the ASH meeting.
15 December 2025
··
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie shares closed at $223.32 Friday, down 0.3%, with a market cap near $395 billion. HSBC upgraded the stock to Buy with a $265 target, and Morgan Stanley lifted its target to $269, citing strong growth from Skyrizi and Rinvoq offsetting Humira declines. AbbVie raised 2025 adjusted EPS guidance to $10.61–$10.65 and announced a 5.5% dividend increase to $1.73 per share quarterly.
14 December 2025
··
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer shares closed at $25.85 Friday, Dec. 12, with volume near 50.8 million. The company declared a $0.43 per share dividend for Q1 2026, marking its 349th consecutive payout. New trial data showed Tukysa cut risk of progression or death in HER2+ metastatic breast cancer by about 36%. Investors remain focused on dividend sustainability and pipeline developments.
14 December 2025
··
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly shares last closed at $1,027.51 as investors weigh advances in obesity drugs and new manufacturing plans. Retatrutide, the company’s next-generation obesity treatment, showed 28.7% average weight loss in a Phase 3 trial, with more studies due in 2026. Lilly also announced a $6 billion API plant in Alabama. Orforglipron, an oral obesity drug, may see an accelerated FDA review.
14 December 2025
··
1 … 21 22 23 24 25 … 34

Stock Market Today

Nvidia stock ‘cheap’ again? AI spending surge puts NVDA back in the spotlight

Nvidia stock ‘cheap’ again? AI spending surge puts NVDA back in the spotlight

8 February 2026
Nvidia shares jumped 7.8% Friday, leading a rally in chip stocks after signs of continued AI hardware spending by major tech firms. The PHLX semiconductor index rose 5.7%, with AMD and Broadcom also gaining. The Dow closed above 50,000 for the first time. Investors remain split over whether soaring AI outlays will deliver sufficient returns.
Go toTop